tazarotene cream
Selected indexed studies
- Efficacy and safety of topical treatments for seborrheic keratoses: a systematic review. (J Dermatolog Treat, 2023) [PMID:36215682]
- Safety, Tolerability, and Pharmacokinetics of Tazarotene Clindamycin Cream: A Single-Dose, 3-Period Crossover Study. (Clin Pharmacol Drug Dev, 2021) [PMID:33241616]
- In Vitro Rheology Predicts Improved Spreadability of Tazarotene 0.045% Lotion Versus Trifarotene 0.005% Cream. (J Drugs Dermatol, 2022) [PMID:35254756]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Efficacy and safety of topical treatments for seborrheic keratoses: a systematic review. (2023) pubmed
- Safety, Tolerability, and Pharmacokinetics of Tazarotene Clindamycin Cream: A Single-Dose, 3-Period Crossover Study. (2021) pubmed
- In Vitro Rheology Predicts Improved Spreadability of Tazarotene 0.045% Lotion Versus Trifarotene 0.005% Cream. (2022) pubmed
- Tazarotene/Betamethasone Dipropionate Cream in Patients with Plaque Psoriasis: Results of a Prospective, Multicenter, Observational Study. (2021) pubmed
- Low irritation potential of tazarotene 0.045% lotion: Head-to-head comparison to adapalene 0.3% gel and trifarotene 0.005% cream in two studies. (2023) pubmed
- Tazarotene 0.1% cream for the treatment of photodamage. (2004) pubmed
- Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. (1998) pubmed
- Simultaneous determination of tazarotene, clindamycin phosphate and their active metabolites in Bama mini-pig skin by LC-MS/MS: Application to the development of a tazarotene/clindamycin phosphate cream. (2021) pubmed
- A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream in the Treatment of Moderate-to-Severe Acne Vulgaris. (2019) pubmed
- Tazarotene cream for the treatment of facial photodamage: a multicenter, investigator-masked, randomized, vehicle-controlled, parallel comparison of 0.01%, 0.025%, 0.05%, and 0.1% tazarotene creams with 0.05% tretinoin emollient cream applied once daily for 24 weeks. (2001) pubmed